Park Ha Biological Technology Co., Ltd.

Park Ha Biological Technology reported a significant reduction in net loss for the six months ended April 30, 2026, narrowing by 95% to $918,282. This improvement was largely due to the absence of a large share-based payment expense recognized in the prior year. Total revenue saw a modest 1% increase, driven by strong product sales growth to non-franchisees, which offset a 35% decline in franchise fees revenue due to a decrease in the number of franchisees. The company also experienced increased selling, marketing, and R&D expenses, and a shift to negative operating cash flow.

Park Ha Biological Technology Co., Ltd. adopted an Amended and Restated Memorandum and Articles of Association on July 13, 2026. This update establishes a dual-class share structure, featuring Class A ordinary shares with one vote per share and Class B ordinary shares with 100 votes per share. Class B shares are convertible into Class A shares on a one-for-one basis at the holder's option. The company's total authorized share capital is $300 million, divided into 300 billion ordinary shares.

Park Ha Biological Technology Co., Ltd. announced the official approval and completion of registration for its North American Amazon store. This marks a significant step in the company's global expansion strategy, leveraging Amazon's platform to access the high-end consumer market. The move is expected to enhance brand exposure, refine product offerings for the North American market, and establish the company as a globally influential brand.

Park Ha Biological Technology Co., Ltd. announced the successful opening of its cross-border store on Amazon North America, completing all registration procedures. This achievement represents a critical milestone in the company's global expansion strategy, signifying its evolution from a premium domestic brand to an emerging international brand. The company plans to leverage Amazon's global traffic, Fulfillment by Amazon (FBA) logistics, and big data resources to tailor its product portfolio for North American markets and enhance international brand exposure. This strategic move aims to establish Park Ha Biological as a benchmark domestic brand with global influence.

Park Ha Biological Technology Co., Ltd. will hold an Extraordinary General Meeting and a Class A Meeting on July 13, 2026, to seek shareholder approval for several significant corporate actions. Key proposals include a substantial increase in the company's authorized share capital from US$3 million to US$300 million, and authorization for the Board to implement share consolidations or subdivisions within a three-year period. Additionally, shareholders will vote on increasing the voting rights of Class B Ordinary Shares from 20 to 100 votes per share, and adopting new Articles of Association.

Park Ha Biological Technology Co., Ltd. announced it has formally filed a complete membership application with the Personal Care Products Council (PCPC). This strategic move aims to establish a comprehensive compliance framework for the North American market and facilitate the company's planned entry into Amazon's North America marketplace. The application, encompassing all requisite corporate and product compliance documentation, is a cornerstone of its international expansion strategy.

Park Ha Biological Technology Co., Ltd. announced a significant global expansion by initiating cooperation with Amazon North America to enter the North American personal care market. This strategic move aims to deepen market presence, enhance international brand equity, and deliver Eastern-inspired skincare products globally. The company is currently advancing four key workstreams, including store qualification and compliance, with overall progress ahead of schedule.

Park Ha Biological Technology Co., Ltd. announced a strategic partnership with Cloud Factory Technology Holdings Limited (02512.HK) to develop an AI-driven ecosystem for the beauty industry. This collaboration aims to leverage cross-domain technological expertise to overcome traditional growth limitations and usher in a new era of AI-powered, lean operations. The partnership will focus on enhancing organizational efficiency, optimizing store space utilization, and improving supply chain and inventory management through AI.

Park Ha Biological Technology Co., Ltd. announced the closing of its previously announced registered direct offering, generating approximately $2.0 million in gross proceeds. The offering involved the sale of 1,133,332 Class A ordinary shares and pre-funded warrants to purchase up to 200,000 Class A ordinary shares, at a combined purchase price of $1.50 per share and warrant. The company plans to utilize the net proceeds for general corporate and working capital purposes.

Park Ha Biological Technology Co., Ltd. announced the pricing of a registered direct offering to raise approximately $2.0 million in gross proceeds. The offering includes up to 1,133,332 Class A ordinary shares and pre-funded warrants to purchase up to 200,000 Class A ordinary shares, at a combined purchase price of $1.50 per share and pre-funded warrant. The company intends to use the net proceeds for general corporate and working capital purposes, with the offering expected to close around June 15, 2026.